TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo

被引：3
|
作者：
Liang, Apeng
Dong, Shengli
Liu, Guangbin
Guo, Zhengfei
Li, Meihua
Han, Shuaibo
Cao, Yundi
Tu, Yian
Zhou, Chao
Yu, Yu
Xiao, Linglin
Huang, Wei
Yang, Xinlong
Fang, Lian
Li, Haoyun
Niu, Chengshan
Jiang, Mingyu
Xing, Feng
Chen, Shaoqing
Li, Jun
Wu, Yusheng
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4491
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo
    Li Xiao
    Liu Yan
    Wen Zhongmei
    Li Chang
    Lu Huijun
    Tian Mingyao
    Jin Kuoshi
    Sun Lili
    Gao Pegn
    Yang Encheng
    Xu Xiaohong
    Kan Shifu
    Wang Zhuoyue
    Wang Yuhang
    Jin Ningyi
    MOLECULAR CANCER, 2010, 9
  • [22] SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo
    Hu, Shanhu
    Marineau, Jason
    Hamman, Kristin
    Bradley, Michael
    Savinainen, Anneli
    Alnemy, Sydney
    Rajagopal, Nisha
    Orlando, David
    Chuaqui, Claudio
    Olson, Eric
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Anti-tumor effect of orally available small molecule PD-L1 inhibitors in a murine model of colon adenocarcinoma
    Li, Shijie
    Vilalta, Marta
    Ertl, Linda S.
    Wang, Yu
    Zeng, Yibin
    Fan, Pingchen
    Lange, Christopher
    McMurtrie, Darren
    Yang, Ju
    Lui, Rebecca
    Ong, Ryan
    Chhina, Vicky
    Kumamoto, Alice
    Yau, Simon
    Dang, Ton
    Easterday, Ashton
    Liu, Shirley
    Singh, Rajinder
    Charo, Israel
    Schall, Thomas J.
    Zhang, Penglie
    CANCER RESEARCH, 2020, 80 (16)
  • [24] BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity
    Scholz, Arne
    Luecking, Ulrich
    Siemeister, Gerhard
    Lienau, Philip
    Eis, Knut
    Wengner, Antje
    Petersen, Kirstin
    Boemer, Ulf
    Nussbaumer, Peter
    Choidas, Axel
    Ruehter, Gerd
    Eickhoff, Jan
    Schultz-Fademrecht, Carsten
    Klebl, Bert
    Ince, Stuart
    von Nussbaum, Franz
    Mumberg, Dominik
    Brands, Michael
    Ziegelbauer, Karl
    CANCER RESEARCH, 2014, 74 (19)
  • [25] CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity
    Lee, Clarissa
    Bhupathi, Deepthi
    Billedeau, Roland
    Chen, Jason
    Chen, Lijing
    Dang, Rosalyn
    Gross, Matthew
    Huang, Tony
    Li, Weiqun
    Ma, Yong
    MacKinnon, Andrew
    Marguier, Gisele
    Neou, Silinda
    Parlati, Francesco
    Sotirovska, Natalija
    Spurlock, Sandra
    Stanton, Timothy
    Steggerda, Susanne
    Zhang, Jing
    Zhang, Winter
    Li, Jim
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] An orally bioavailable small molecule antagonist of VISTA and VSIG8 signaling pathways shows potent anti-tumor activity
    Sasikumar, Pottayil
    Naremaddepalli, Sudarshan
    Ramachandra, Raghuveer
    Gowda, Nagesh
    Alluri, Govardhan
    Yerramsetti, Manikyalarao
    Adurthi, Sreenivas
    Mani, Jiju
    Nair, Rashmi
    Dhudashiya, Amit
    Dodheri, Samiulla
    Gowda, Nagaraj
    Ramachandra, Murali
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] SY-7021, a novel DNA-PK inhibitor, exhibits significant anti-tumor activity in vitro and in vivo
    Zhang, Kai
    Liu, Zhihua
    Gao, Yuhao
    Lu, Chang
    Cheng, Shikang
    Liu, Xijie
    Luo, Hong
    Sun, Yinghui
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Targeting PKC in multiple myeloma:: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCI).
    Raab, Marc S.
    Podar, Klaus
    Zhang, Jing
    McMillin, Douglas
    Breitkreutz, Iris
    Tai, Yu-Tzu
    Lin, Boris
    Ghobrial, Irene
    Munshi, Nikhil
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2006, 108 (11) : 989A - 989A
  • [29] Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
    Podar, Klaus
    Raab, Marc S.
    Zhang, Jing
    McMillin, Douglas
    Breitkreutz, Iris
    Tai, Yu-Tzu
    Lin, Boris K.
    Munshi, Nikhil
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2007, 109 (04) : 1669 - 1677
  • [30] EG-011 is a novel small molecule with in vitro and in vivo anti-tumor activity against lymphoma
    Gaudio, Eugenio
    Spriano, Filippo
    Tarantelli, Chiara
    Guala, Matilde
    Riveiro, Eugenia
    Golino, Gaetanina
    Lupia, Antonio
    Costa, Giosue
    Rocca, Roberta
    Cascione, Luciano
    Jenni, Silvia
    Tsai, Yi-Chien
    Bornhauser, Beat
    Alcaro, Stefano
    Paduano, Francesco
    Trapasso, Francesco
    Zucca, Emanuele
    Stathis, Anastasios
    Pazzi, Natalina
    Cavalli, Franco
    Bertoni, Francesco
    CANCER RESEARCH, 2019, 79 (13)
12345